Engflag

Arbitel-H

Quick links to important sections

Arbitel-H

Arbitel-H_EN

Method of action: Antihypertensive, Diuretic

Treatment option: Hypertension

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arbitel-H

Arbitel-H is a prescription-only medication identified as a synthetic, fixed-dose combination product for the management of essential hypertension (chronic high blood pressure) in adults. The drug is administered via oral administration as a single tablet and is structurally defined by its dual mechanism of action, a combination strategy supported by extensive pharmacological studies.

Property Description
Active ingredients Telmisartan, Hydrochlorothiazide (HCTZ)
Form Tablet (Uncoated Bilayered)
Pharmacological class Angiotensin II Receptor Antagonist (ARB) and Thiazide Diuretic Combination
Common use Managing Essential Hypertension
Origin Synthetic

Composition and Pharmacological Dual Action

The medication's dual activity results from its two active ingredients: Telmisartan and Hydrochlorothiazide (HCTZ), both of which are synthetic compounds. Telmisartan is an Angiotensin II Receptor Antagonist (ARB), a pharmacological class designed to block the effects of a specific hormone that constricts blood vessels. Hydrochlorothiazide is a Thiazide Diuretic, commonly referred to as a "water pill," that works primarily by affecting kidney function to increase the excretion of sodium and water. This combination strategy is one of several popular brands available globally with this same formulation.

General Therapeutic Goal and Combined Benefit

The overarching goal of Arbitel-H therapy is to achieve a sustained reduction in blood pressure to mitigate serious long-term health risks. This sustained effect is supported by extensive pharmacological studies validating the complementary roles of the ARB and the diuretic. The primary general benefit of controlling high blood pressure in this manner is the significant mitigation of risk associated with severe cardiovascular events, including stroke and myocardial infarction. The drug is intended for adult patients whose blood pressure requires this comprehensive, two-pronged approach.

What side effects are possible with Arbitel-H?

Possible Side Effects and Safety Information

The official documentation of Arbitel-H provides detailed classification of possible side effects based on system-organ class and documented frequency, reflecting patterns observed during clinical use. Safety information is grouped by the frequency of occurrence documented in regulatory studies and post-marketing surveillance.

Common Adverse Reactions

Reactions classified as common in official labeling typically affect Metabolism and nutrition disorders, often involving disturbances such as hypokalemia (low potassium levels) and hyperuricemia (elevated uric acid). Effects on the Nervous system disorders and General disorders are also frequently noted, including experiences like dizziness and fatigue. Reactions such as back pain are documented under Musculoskeletal and connective tissue disorders.

Uncommon and Rare Documented Effects

Adverse reactions documented as less common span various system-organ classes. Vascular disorders may include hypotension (low blood pressure), which may be more likely to manifest at the start of treatment or during dose escalation. More significant but rare reactions documented in official sources, particularly in the Immune system disorders and Skin and subcutaneous tissue disorders, include angioedema (swelling of the face, lips, or throat) and, in very rare instances, severe dermatological reactions.

Documented Serious Adverse Reactions

Official regulatory documentation highlights the potential for serious adverse reactions. These include anaphylactic reaction, acute renal failure, and significant hepatic dysfunction (sometimes progressing to jaundice). These serious events are monitored and formally documented within the official safety profile.

Population-Specific Safety Constraints

Specific constraints regarding usage in certain populations are stated. The product is contraindicated in individuals with anuria (absence of urine flow) and those with severe renal impairment or severe hepatic impairment. Furthermore, the drug is strictly contraindicated in the second and third trimesters of pregnancy due to associated risks.

Overdose and Emergency Response

The regulatory documentation for Arbitel-H, a fixed-dose combination product, describes overdose through severe physiological consequences resulting from the actions of its two components. The primary manifestation is Profound Hypotension (markedly low blood pressure), which may be accompanied by heart rate changes such as tachycardia or bradycardia. The diuretic component causes severe fluid and electrolyte disturbances, notably Hypokalemia (low potassium) and Hyponatremia (low sodium), often presenting with dizziness, lethargy, or signs of dehydration.

When to Seek Immediate Help

Regulatory authorities explicitly mandate that individuals must seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the patient shows serious signs like collapse, seizure, unresponsiveness, or trouble breathing. The regulatory profile documents severe outcomes, including the risk of circulatory shock and acute renal failure due to volume depletion. Treatment is officially defined as symptomatic and supportive, and no specific antidote is known. The labeling also contains a specific warning that exposure during the second or third trimester of pregnancy is associated with risks of neonatal hypotension, renal failure, and death.

Therapeutic Uses of Arbitel-H

What Arbitel-H Treats: Main Uses and Benefits

Arbitel-H is a combination medication that is commonly used in situations involving the management of essential hypertension (high blood pressure). It is relevant in clinical settings that involve more challenging symptom patterns. This drug is indicated for the treatment of hypertension.

The main therapeutic benefit contributes to improved day-to-day comfort by supporting blood pressure within a healthier range. Additionally, the medication may also assist with symptoms of excess fluid retention (oedema or swelling).

In clinical settings, it is often used during phases when symptoms become more noticeable. This therapeutic approach may assist with maintaining functional stability by helping to manage cardiovascular stress.

“This medicine supports patients during episodes of heightened discomfort by easing the overall symptom load.”

Quick Fact: Relief for Elevated Blood Pressure The medication helps address symptoms related to systemic imbalance that may interfere with daily functioning by contributing to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. DailyMed (NIH) prescribing information for Telmisartan and Hydrochlorothiazide

Eligibility and Restrictions for Use

Who Can and Cannot Use Arbitel-H?

Eligibility for Arbitel-H (Telmisartan/Hydrochlorothiazide) is strictly defined by regulatory authorities and centers on the adult population with essential hypertension not adequately controlled by either single component.

Contraindications and Prohibited Use

Arbitel-H is contraindicated (absolutely prohibited) in patients with severe hepatic impairment (including cholestasis) and severe renal impairment (creatinine clearance < 30 mL/min or anuria). It must not be used during the second and third trimesters of pregnancy, or by individuals with known hypersensitivity to its components or to sulphonamide-derived medicines (HCTZ). Co-administration with Aliskiren is contraindicated for patients with diabetes or existing renal impairment.

Restricted and Non-Recommended Groups

Population Group Regulatory Status
Children and Adolescents (Below 18 years) Not Recommended (Safety/efficacy not established)
Pregnancy (First Trimester) Not Recommended
Lactation/Breastfeeding Not Recommended

Use requires special caution, but is not contraindicated, in patients with mild to moderate hepatic impairment and those with existing volume or sodium depletion (which must be corrected before administration).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define several clinically significant interactions for Arbitel-H, a combination of Telmisartan and Hydrochlorothiazide (HCTZ), primarily concerning additive effects on blood pressure and electrolytes, as well as altered drug exposure.

Classification Interacting Agents Regulatory Constraint
Contraindicated Combination Aliskiren Prohibited in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m^2) [1.4, 3.1].
Increased Exposure Risk Lithium Use requires close monitoring, as the HCTZ component reduces Lithium's renal clearance, potentially leading to toxicity [2.1].
Digoxin Telmisartan is an inhibitor of P-glycoprotein (P-gp), resulting in increased plasma concentrations of Digoxin [2.3, 3.4].
Reduced Efficacy/Risk Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the blood pressure lowering effect and increase the risk of renal function deterioration [1.2, 2.4].
Required Timing Separation Cholestyramine, Colestipol Must be administered at least 4 hours before or 4 to 6 hours after Arbitel-H to prevent reduced HCTZ absorption [2.4].

Co-administration with other agents that affect potassium, such as potassium supplements or corticosteroids, can intensify the risk of either hyperkalemia (Telmisartan component) or hypokalemia (HCTZ component) [1.2, 2.3]. The label also notes that alcohol may cause an additive hypotensive effect [1.3]. Furthermore, the drug is not recommended for use in patients with severe hepatic or severe renal impairment due to expected reduced clearance of Telmisartan and HCTZ, respectively [1.4, 2.2]. These statements define constraints for co-administration, based strictly on official regulatory findings.

Mechanism of Action

Arbitel-H functions via a coordinated dual-mechanism approach, modulating both receptor signaling and enzymatic activity within relevant physiological systems.

Component H acts as a competitive antagonist by binding specifically to the Target X Receptor site. This molecular interaction induces a conformational change that allosterically restricts the downstream activation of the Signaling Cascade Y. The consequence of this cellular event is the modulation of osteoclast-mediated bone resorption, thereby influencing the kinetics of skeletal turnover.

Simultaneously, the second component, Arbitel, interacts upstream by promoting the sequestration of key biochemical markers and inhibiting the activity of Enzyme Z. This mechanism of concentration-dependent inhibition results in a decreased intracellular production rate of specific pro-inflammatory cytokines. This coordinated dual-component action alters the homeostatic set point of the Feedback Loop A at the cellular and tissue level.

Dosage and Administration Information

How Arbitel-H is Used: Official Administration Guidelines

Arbitel-H (Telmisartan/Hydrochlorothiazide) is a prescription-only medication and must be used strictly according to the regimen outlined in official prescribing information. This fixed-dose combination is generally reserved for adult patients whose blood pressure is not adequately controlled by either component used alone (monotherapy) and is not intended for initial therapy of essential hypertension.

Administration and Dosage Schedule

The approved route of administration is oral, with the tablet swallowed whole. Official instructions specify a once daily dosing schedule.

Parameter Official Use Instruction
Route of Administration Oral administration (swallow tablet whole).
Dosing Frequency Once daily administration.
Timing Relative to Meals May be taken with or without food.
Common Strength Ranges 40 mg/12.5 mg and 80 mg/12.5 mg (Telmisartan/HCTZ).
Maximum Dose The maximum recommended daily fixed-dose combination is 80 mg/25 mg.

Contextual and Population-Specific Use

To ensure efficacy, the tablet should be taken out of its sealed blister pack only immediately before use.

Official labeling also specifies dose adjustments for specific patient groups:

  • Hepatic Impairment: Patients with mild to moderate liver impairment should not exceed the 40 mg/12.5 mg dose. The combination is not recommended for severe hepatic impairment.
  • Renal Impairment: Use is not recommended in patients with severe kidney impairment (creatinine clearance <30 mL/min).

Recent Clinical Evidence

The research base for Arbitel-H (Telmisartan/Hydrochlorothiazide) is designed to explore its use in managing chronic high blood pressure. This summary describes the types of studies conducted and what areas remain uncertain.

Evidence for Use in The condition of Essential Hypertension

The foundation of the research for this combination medication rests on Randomized Controlled Trials (RCTs), many of which were short-term, and Meta-analyses that was applied in research contexts involving adults with chronic high blood pressure. These studies were evaluated in by comparing measured blood pressure data from patients taking the combination against those taking an inactive placebo and those taking only one of the two active ingredients. Studies primarily focused on outcomes monitoring physiological strain or stress by measuring seated Systolic and Diastolic Blood Pressure (SBP and DBP). Research describes patterns observed in the studies related to achieving specific blood pressure targets over defined time intervals.

Outcomes Studied in Relation to Cardiovascular Risk

Beyond immediate blood pressure measurement, the broader evidence landscape, often supported by studies of the Telmisartan monocomponent, was evaluated in large patient groups to explore outcomes monitoring physiological strain or stress. These long-term studies monitored the occurrence of major events over time, such as stroke and myocardial infarction (heart attack). Research has explored whether data show patterns related to cardiovascular events, often relying on findings from the extensive research available for the monocomponent, Telmisartan.

What Research Gaps and Uncertainty Remain

Most combination RCTs were applied in studies examining short-term changes, typically lasting 8 weeks or less. Evidence related to the durability and consistency of the measurements over extended periods is often limited. While there are large Observational/Cohort Studies that extended follow-up durations up to three years or more—primarily for the single-agent drug—the available information regarding long-term effects specifically for the fixed-dose combination is not fully established. Data for certain groups remain insufficient, with limited information available for some elderly populations. Research contributes to understanding short-term changes, but certainty remains low regarding the direct, long-term impact of the fixed-dose combination on Major Adverse Cardiovascular Events.

Key Studies & References Study Details | NCT00239369 | Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5 (A Non-Responders Trial)

How should Arbitel-H be stored and disposed of?

How to Store and Dispose of Arbitel-H?

Arbitel-H (Telmisartan and Hydrochlorothiazide) must be stored strictly according to its official regulatory labeling to maintain stability. The medicine must be kept out of the sight and reach of children.

Storage Requirements

Condition Requirement
Temperature Store below 30°C or at controlled room temperature, and keep from freezing.
Protection Keep in the original package and sealed blister to protect the hygroscopic tablets from moisture and light.
Handling Only remove the tablet from the blister shortly before administration (do not pre-sort).

Disposal Requirements

Do not use Arbitel-H after the expiry date printed on the carton. Unused or expired medication must not be thrown away indiscriminately but should be disposed of according to local regulations or a drug take-back program. Consult a pharmacist regarding the proper disposal of any unwanted product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Arbitel-H found in:

A-Z Index: